MedTrace Logo

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

NCT06247488 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2024-08-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the abuse potential of gabapentin enacarbil immediate release capsules taken alone and in combination with oxycodone in healthy adult, non-dependent, recreational opioid users.

Conditions

  • Abuse Potential

Interventions

DRUG

Placebo

Participant will receive oral dose of placebo.

DRUG

Oxycodone 20 mg

Participant will receive oral dose of oxycodone 20 mg.

DRUG

GE-IR 200 mg

Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.

DRUG

GE-IR 450 mg

Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.

Sponsors & Collaborators

  • Arbor Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2023-04-25
Completion
2023-04-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06247488 on ClinicalTrials.gov